UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on Alnylam Pharmaceuticals Following R&D Day

In a report published Friday, Deutsche Bank analyst Alethia Young reiterated a Buy rating on

, and raised the price target from $40.00 to $60.00. In the report, Deutsche Bank noted, “After R&D day and subQ top-line data, we are more confident that subQ dosing is a platform game changer and believe delivery technology is de-risked. The subQ dose allows the company to pursue many therapeutic targets in high unmet need areas. Maintain Buy.” Alnylam Pharmaceuticals closed on Thursday at $43.53.